Vor Biopharma (VOR)
(Delayed Data from NSDQ)
$0.83 USD
+0.01 (1.33%)
Updated Aug 13, 2024 03:59 PM ET
After-Market: $0.83 0.00 (-0.02%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Vor Biopharma Inc. (VOR) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$13.50 | $22.00 | $10.00 | 1,546.34% |
Price Target
Based on short-term price targets offered by seven analysts, the average price target for Vor Biopharma Inc. comes to $13.50. The forecasts range from a low of $10.00 to a high of $22.00. The average price target represents an increase of 1% from the last closing price of $0.82.
Analyst Price Targets (7 )
Broker Rating
Vor Biopharma Inc. currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on seven recommendations.
Of the seven recommendations deriving the current ABR, seven are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 7 | 7 | 7 | 7 | 7 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.25 | 1.25 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/8/2024 | Wedbush Securities | David M Nierengarten | Strong Buy | Strong Buy |
8/8/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/13/2024 | JMP Securities | Silvan C Tuerkcan | Strong Buy | Strong Buy |
3/1/2024 | H.C. Wainwright & Co. | Swayampakula Ramakanth | Strong Buy | Strong Buy |
2/15/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
2/1/2024 | Robert W. Baird & Co. | Jack K Allen | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 7 |
Average Target Price | $13.50 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 71 of 253 |
Current Quarter EPS Est: | -0.40 |